These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 24599014)

  • 1. Effects of prescribed antihypertensives and other cardiovascular drugs on mortality in patients with atrial fibrillation and hypertension: a cohort study from Sweden.
    Carlsson AC; Wändell P; Sundquist K; Johansson SE; Sundquist J
    Hypertens Res; 2014 Jun; 37(6):553-9. PubMed ID: 24599014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihypertensive drugs and relevant cardiovascular pharmacotherapies and the risk of incident dementia in patients with atrial fibrillation.
    Wändell P; Carlsson AC; Sundquist J; Sundquist K
    Int J Cardiol; 2018 Dec; 272():149-154. PubMed ID: 30072151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapy and mortality in atrial fibrillation--a cohort of men and women 75 years or older in Sweden.
    Wändell PE; Carlsson AC; Sundquist J; Johansson SE; Bottai M; Sundquist K
    Age Ageing; 2015 Mar; 44(2):232-8. PubMed ID: 25324331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of cardiovascular drugs on mortality in atrial fibrillation and chronic heart failure.
    Wändell P; Carlsson AC; Sundquist J; Johansson SE; Bottai M; Sundquist K
    Scand Cardiovasc J; 2014 Oct; 48(5):291-8. PubMed ID: 25022789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K; Hornestam B; Lehto M; Slotwiner DJ; Gerdts E; Olsen MH; Aurup P; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Rokkedal J; Devereux RB
    J Am Coll Cardiol; 2005 Mar; 45(5):705-11. PubMed ID: 15734614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation: A Report From the GARFIELD-AF Registry.
    Corbalan R; Bassand JP; Illingworth L; Ambrosio G; Camm AJ; Fitzmaurice DA; Fox KAA; Goldhaber SZ; Goto S; Haas S; Kayani G; Mantovani LG; Misselwitz F; Pieper KS; Turpie AGG; Verheugt FWA; Kakkar AK;
    JAMA Cardiol; 2019 Jun; 4(6):526-548. PubMed ID: 31066873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renin-angiotensin-aldosterone system inhibitors and mortality risk in elderly patients with atrial fibrillation. Insights from the nationwide START registry.
    Menichelli D; Poli D; Antonucci E; Palareti G; Pignatelli P; Pastori D;
    Eur J Intern Med; 2024 Jan; 119():84-92. PubMed ID: 37648584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study.
    Schaer BA; Schneider C; Jick SS; Conen D; Osswald S; Meier CR
    Ann Intern Med; 2010 Jan; 152(2):78-84. PubMed ID: 20083826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K; Lehto M; Gerdts E; Olsen MH; Hornestam B; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Devereux RB
    J Am Coll Cardiol; 2005 Mar; 45(5):712-9. PubMed ID: 15734615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
    Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
    J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations between relevant cardiovascular pharmacotherapies and incident heart failure in patients with atrial fibrillation: a cohort study in primary care.
    Wändell P; Carlsson AC; Holzmann MJ; Ärnlöv J; Sundquist J; Sundquist K
    J Hypertens; 2018 Sep; 36(9):1929-1935. PubMed ID: 29870433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihypertensive treatment and risk of atrial fibrillation: a nationwide study.
    Marott SC; Nielsen SF; Benn M; Nordestgaard BG
    Eur Heart J; 2014 May; 35(18):1205-14. PubMed ID: 24347316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of cardiovascular drugs and risk of incident heart failure in patients with atrial fibrillation.
    Wändell P; Carlsson AC; Li X; Holzmann MJ; Sundquist J; Sundquist K
    J Clin Hypertens (Greenwich); 2020 Aug; 22(8):1396-1405. PubMed ID: 32667702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of cardiovascular pharmacotherapies on incident dementia in patients with atrial fibrillation: A cohort study of all patients above 45 years diagnosed with AF in hospitals in Sweden.
    Wändell P; Carlsson AC; Li X; Sundquist J; Sundquist K
    Int J Cardiol; 2019 Dec; 297():55-60. PubMed ID: 31619361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of statins and antihypertensive medications in relation to risk of long-standing persistent atrial fibrillation.
    Thacker EL; Jensen PN; Psaty BM; McKnight B; Longstreth WT; Dublin S; Newton KM; Smith NL; Siscovick DS; Heckbert SR
    Ann Pharmacother; 2015 Apr; 49(4):378-86. PubMed ID: 25628466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence with treatment in newly treated middle-aged patients with essential hypertension.
    Perreault S; Lamarre D; Blais L; Dragomir A; Berbiche D; Lalonde L; Laurier C; St-Maurice F; Collin J
    Ann Pharmacother; 2005 Sep; 39(9):1401-8. PubMed ID: 16076920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
    Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB
    Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
    Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
    Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined hypotensive treatment with ≥ 3 hypotensive drugs in patients with recurrent atrial fibrillation and arterial hypertension ensures more effective arrhythmia control than using less drugs.
    Kowalik I; Dąbrowski R; Borowiec A; Smolis Bąk E; Sosnowski C; Szwed H
    Kardiol Pol; 2012; 70(7):659-66. PubMed ID: 22825936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients.
    Deftereos S; Giannopoulos G; Kossyvakis C; Efremidis M; Panagopoulou V; Raisakis K; Kaoukis A; Karageorgiou S; Bouras G; Katsivas A; Pyrgakis V; Stefanadis C
    Am J Cardiol; 2013 Sep; 112(5):684-7. PubMed ID: 23726175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.